Banerjee Mousumi, Wiebel Jaime L, Guo Cui, Gay Brittany, Haymart Megan R
Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA Institute for Healthcare Policy and Innovation (IHPI), University of Michigan, Ann Arbor, MI 48109, USA.
Endocrine Associates of Dallas, Dallas, TX, USA.
BMJ. 2016 Jul 20;354:i3839. doi: 10.1136/bmj.i3839.
To determine whether the use of imaging tests after primary treatment of differentiated thyroid cancer is associated with more treatment for recurrence and fewer deaths from the disease.
Population based retrospective cohort study.
Surveillance Epidemiology and End Results-Medicare database in the United States.
28 220 patients diagnosed with differentiated thyroid cancer between 1998 and 2011. The study cohort was followed up to 2013, with a median follow-up of 69 months.
Treatment for recurrence of differentiated thyroid cancer (additional neck surgery, additional radioactive iodine treatment, or radiotherapy), and deaths due to differentiated thyroid cancer. We conducted propensity score analyses to assess the relation between imaging (neck ultrasound, radioiodine scanning, or positron emission tomography (PET) scanning) and treatment for recurrence (logistic model) and death (Cox proportional hazards model).
From 1998 until 2011, we saw an increase in incident cancer (rate ratio 1.05, 95% confidence interval 1.05 to 1.06), imaging (1.13, 1.12 to 1.13), and treatment for recurrence (1.01, 1.01 to 1.02); the change in death rate was not significant. In multivariable analysis, use of neck ultrasounds increased the likelihood of additional surgery (odds ratio 2.30, 95% confidence interval 2.05 to 2.58) and additional radioactive iodine treatment (1.45, 1.26 to 1.69). Radioiodine scans were associated with additional surgery (odds ratio 3.39, 95% confidence interval 3.06 to 3.76), additional radioactive iodine treatment (17.83, 14.49 to 22.16), and radiotherapy (1.89, 1.71 to 2.10). Use of PET scans was associated with additional surgery (odds ratio 2.31, 95% confidence interval 2.09 to 2.55), additional radioactive iodine treatment (2.13, 1.89 to 2.40), and radiotherapy (4.98, 4.52 to 5.49). Use of neck ultrasounds or PET scans did not significantly affect disease specific survival (hazard ratio 1.14, 95% confidence interval 0.98 to 1.27, and 0.91, 0.77 to 1.07, respectively). However, radioiodine scans were associated with an improved disease specific survival (hazard ratio 0.70, 95% confidence interval 0.60 to 0.82).
The marked rise in use of imaging tests after primary treatment of differentiated thyroid cancer has been associated with an increased treatment for recurrence. However, with the exception of radioiodine scans in presumed iodine avid disease, this association has shown no clear improvement in disease specific survival. These findings emphasize the importance of curbing unnecessary imaging and tailoring imaging after primary treatment to patient risk.
确定分化型甲状腺癌初次治疗后进行影像学检查是否与更多的复发治疗及更低的疾病死亡率相关。
基于人群的回顾性队列研究。
美国监测、流行病学与最终结果-医疗保险数据库。
1998年至2011年间确诊为分化型甲状腺癌的28220例患者。研究队列随访至2013年,中位随访时间为69个月。
分化型甲状腺癌复发的治疗(额外的颈部手术、额外的放射性碘治疗或放疗)以及分化型甲状腺癌导致的死亡。我们进行倾向得分分析以评估影像学检查(颈部超声、放射性碘扫描或正电子发射断层扫描(PET))与复发治疗(逻辑模型)及死亡(Cox比例风险模型)之间的关系。
从1998年至2011年,我们观察到新发癌症(率比1.05,95%置信区间1.05至1.06)、影像学检查(1.13,1.12至1.13)及复发治疗(1.01,1.01至1.02)均有所增加;死亡率变化不显著。在多变量分析中,使用颈部超声增加了额外手术的可能性(优势比2.30,95%置信区间2.05至2.58)以及额外放射性碘治疗的可能性(1.45,1.26至1.69)。放射性碘扫描与额外手术(优势比3.39,95%置信区间3.06至3.76)、额外放射性碘治疗(17.83,14.49至22.16)及放疗(1.89,1.71至2.10)相关。使用PET扫描与额外手术(优势比2.31,95%置信区间2.09至2.55)、额外放射性碘治疗(2.13,1.89至2.40)及放疗(4.98,4.52至5.49)相关。使用颈部超声或PET扫描对疾病特异性生存无显著影响(风险比分别为1.14,95%置信区间0.98至1.27和0.91,0.77至1.07)。然而,放射性碘扫描与改善的疾病特异性生存相关(风险比0.70,95%置信区间0.60至0.82)。
分化型甲状腺癌初次治疗后影像学检查使用的显著增加与复发治疗的增加相关。然而,除了在疑似碘摄取性疾病中进行放射性碘扫描外,这种关联并未显示出疾病特异性生存有明显改善。这些发现强调了控制不必要的影像学检查以及根据患者风险在初次治疗后进行针对性影像学检查的重要性。